Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

BQ-Technology · BrainQ, non-invasive, very low intensity, BCI-based frequency dependent electromagnetic field tailored treatment for neuro recovery (BQ).

H2020Status: CLOSED1 August 201830 November 2018EU funding €50,000Call H2020-EIC-SMEInst-2018-2020

The WHO has identified neurological disorders as a major burden and emerging challenge to global healthcare systems. These range from causes such as stroke and dementia, to injuries and viral infections. The prevalence of strokes and dementia are strongly linked to increasing age, for example stroke risk more than doubles every decade after 55 . Although, mortality attributable to stroke has decreased over time Stroke remains a leading cause of death and disability globally and can cause significant deficits in sensorimotor skills and cognitive abilities.With the increasingly aging populations across the world and particularly in Europe, the burden of care from Neurological disorders is set to continue increasing.BrainQ’s BQ system is a revolutionary Brain Computer Interface-based stimulation device used to enhance neuro-recovery. Our device uses proprietary, artificial intelligence algorithms to identify anomalous spectral patterns in patient's brain waves (“EEG”). These patterns are then translated into a tailored frequency dependent electromagnetic treatment targeting specific impaired functional neural network associated with these frequencies and triggers natural rehabilitation thus promoting neuro recovery process. Device is designed to enable non-invasive treatment for motor impairments following a variety of neurological disorders; help patients get back on their feet and restore their ability to perform activities of daily living. Treatment is tailored to each patient, is patient friendly, non-invasive, cloud connected & scalable, with low Bill of Materials, and operator & indication agnostic. This means it is easily operated and can be used to treat a variety of neurological disorders. Pre-clinical animal trials and first-in-human clinical trials have demonstrated remarkable efficacy, allowing paralysed patients regain sensor and motor abilities.

Consortium · 1 organisation

coordinator

BRAINQ TECHNOLOGIES LTD

IL · €50,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.